This document outlines details of PBS-subsidised azacitidine, decitabine+cedazuridine and lenalidomide for patients with myelodysplastic syndrome (MDS).
For information on how to process a PBS Authority, see Processing Complex Authority Required Listings. Contact a Local Peer Support (LPS) if unsure of how to action an application.
Myelodysplastic syndrome quick reference
Restrictions | Authority level and section | PA assessment | Processing system | Prescriber type | Prescriber self-serve |
Initial or First Continuing PB012 form | Written Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
Initial | Telephone Electronic S100: azacitidine S85: decitabine+cedazuridine (general listing) | No | OPA | Not specified | Yes |
Subsequent
Continuing | Telephone Electronic S100: lenalidomide | No | OPA | Not specified | Yes |
Continuing | Telephone Electronic S100: azacitidine S85: decitabine+cedazuridine (general listing) | No | OPA | Not specified | Yes |
Expand all